Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Skye Bioscience, Inc. (SKYE)
USD0.61
-0.01 (-2.26%)
US NASDAQ Healthcare Biotechnology
Address
11250 El Camino Real 92130
San Diego, CA, US
San Diego, CA, US
CEO
Punit Dhillon
Website
skyebioscience.com
IPO
2015-01-06
CIK 1516551 ISIN US83086J2006
Description
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.61
-0.01 (-2.26%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
192.8K
Beta
2.93
Float Shares
21.81M
Free Float %
62.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.01% | +1.50% | +22.22% | +22.05% | -42.11% | +17.38% | -57.07% | -76.53% | -96.17% | -99.41% | -99.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.61
Low
2.00
+230.0%
Consensus
12.00
+1,879.9%
Median
15.00
+2,374.8%
High
21.00
+3,364.8%
DCF (Unlevered)
0.10
-83.8%
DCF (Levered)
0.14
-76.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
2.00
+230.0%
|
| All Time | 8 |
15.50
+2,457.3%
|
Quality scores
Altman Z-Score
-10.20
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-93.2% Q1'26: -14.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.7% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 EPS Ana. |
Dec 2027 5 EPS Ana. |
Dec 2028 6 EPS Ana. |
Dec 2029 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
43.45M
43.45M – 43.45M
|
| EBITDA |
-25.29M
|
-57.44M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-25.59M
|
-58.16M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-26.57M
est: -32.89M (+19.2%)
|
-55.92M
est: -55.92M (+0.0%)
|
-46.32M
-51.79M – -23.02M
+17.2% YoY
|
-41.56M
-55.52M – -27.60M
+10.3% YoY
|
-83.14M
-84.85M – -26.56M
-100.0% YoY
|
-64.15M
-64.15M – -64.15M
+22.8% YoY
|
-35.70M
-35.70M – -35.70M
+44.4% YoY
|
| SGA |
17.73M
|
15.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.73
est: -0.86 (+15.2%)
|
-1.41
est: -1.39 (-1.5%)
|
-0.96
-1.31 – -0.58
+30.8% YoY
|
-1.13
-1.40 – -0.70
-17.5% YoY
|
-1.37
-2.14 – -0.67
-21.5% YoY
|
-1.62
-1.62 – -1.62
-17.8% YoY
|
-0.90
-0.90 – -0.90
+44.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.03M
OE per share TTM
-9.99
Owner's Yield
-17.26%
Maintenance CapEx ratio
0.00%
Maint CapEx / Avg PPE
26.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
1.80M
Insider transactions (90d)
0
Beneficial owners (>5%)
42
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Andrew J. Schwab | 1.56B | 44.40% | — | 1.56B | — | 10.00 | IN | United States | 2023-08-28 | ↗ |
| 2 | 5AM Partners VII, LLC | 1.11B | 31.70% | — | 1.11B | — | 10.00 | OO | Delaware | 2023-08-28 | ↗ |
| 3 | 5AM Ventures VII, L.P. | 1.11B | 31.70% | — | 1.11B | — | 10.00 | PN | Delaware | 2023-08-28 | ↗ |
| 4 | Kush Parmar | 1.11B | 31.70% | — | 1.11B | — | 10.00 | IN | United States | 2023-08-28 | ↗ |
| 5 | Versant Ventures III, LLC | 632.74M | 19.70% | — | 632.74M | — | — | OO | Delaware | 2023-08-28 | ↗ |
| 6 | Versant Venture Capital III, L.P. | 629.02M | 19.60% | 629.02M | — | 629.02M | — | PN | Delaware | 2023-08-28 | ↗ |
| 7 | 5AM Partners II, LLC | 446.50M | 14.50% | — | 446.50M | — | 10.00 | OO | Delaware | 2023-08-28 | ↗ |
| 8 | John D. Diekman | 446.50M | 14.50% | — | 446.50M | — | 10.00 | IN | United States | 2023-08-28 | ↗ |
| 9 | Scott M. Rocklage | 446.50M | 14.50% | — | 446.50M | — | 10.00 | IN | United States | 2023-08-28 | ↗ |
| 10 | 5AM Ventures II, L.P. | 429.55M | 13.90% | — | 429.55M | — | 10.00 | PN | Delaware | 2023-08-28 | ↗ |
| 11 | Emerald Health Sciences Inc. | 76.74M | 58.20% | 76.74M | — | 76.74M | — | CO | British Columbia, Canada | 2018-01-30 | ↗ |
| 12 | 5AM Co-Investors II, L.P. | 16.95M | 0.60% | — | 16.95M | — | 10.00 | PN | Delaware | 2023-08-28 | ↗ |
| 13 | Armistice Capital Master Fund Ltd. | 15.19M | 6.30% | — | 15.19M | — | 15.19M | CO | Delaware | 2020-08-10 | ↗ |
| 14 | Armistice Capital, LLC | 15.19M | 6.30% | — | 15.19M | — | 15.19M | IA, OO | Delaware | 2020-08-10 | ↗ |
| 15 | Steven Boyd | 15.19M | 6.30% | — | 15.19M | — | 15.19M | HC, IN | Delaware | 2020-08-10 | ↗ |
| 16 | Michael Bigger | 14.17M | 5.90% | — | — | — | 14.17M | IN | Delaware | 2020-08-07 | ↗ |
| 17 | District 2 Capital Fund LP | 7.08M | 3.00% | — | — | — | 7.08M | PN | Delaware | 2020-08-07 | ↗ |
| 18 | District 2 Capital LP | 7.08M | 3.00% | — | — | — | 7.08M | PN | Delaware | 2020-08-07 | ↗ |
| 19 | District 2 GP LLC | 7.08M | 3.00% | — | — | — | 7.08M | OO | Delaware | 2020-08-07 | ↗ |
| 20 | District 2 Holdings LLC | 7.08M | 3.00% | — | — | — | 7.08M | OO | Delaware | 2020-08-07 | ↗ |
| 21 | Bigger Capital Fund GP, LLC | 7.08M | 3.00% | — | — | — | 7.08M | OO | Delaware | 2020-08-07 | ↗ |
| 22 | Bigger Capital Fund, LP | 7.08M | 3.00% | — | — | — | 7.08M | PN | Delaware | 2020-08-07 | ↗ |
| 23 | Versant Side Fund III, L.P. | 3.72M | 0.10% | 3.72M | — | 3.72M | — | PN | Delaware | 2023-08-28 | ↗ |
| 24 | Richard D. Squires | 1.88M | 11.30% | 1.86M | 18.8K | 1.86M | — | IN | United States of America | 2015-04-20 | ↗ |
| 25 | EIN #00-0000000 | 1.73M | 5.70% | — | 1.73M | — | 1.73M | IA, HC | Jersey, Channel Islands | 2024-08-14 | ↗ |
| 26 | 00-0000000 | 1.59M | 5.20% | — | 1.59M | — | 1.59M | CO | Cayman Islands | 2024-08-14 | ↗ |
| 27 | RDS Holdings, Inc. | 1.50M | 9.40% | — | 1.50M | — | — | CO | Texas | 2014-12-17 | ↗ |
| 28 | Altium Capital Management, LP | 1.30M | 5.40% | — | 1.30M | — | — | IA, PN | Delaware, United States of America | 2024-02-05 | ↗ |
| 29 | Altium Growth Fund, LP | 1.30M | 5.40% | — | 1.30M | — | — | PN | Delaware, United States of America | 2024-02-05 | ↗ |
| 30 | Altium Growth GP, LLC | 1.30M | 5.40% | — | 1.30M | — | — | OO | Delaware, United States of America | 2024-02-05 | ↗ |
| 31 | Sphera Funds Management Ltd. | 1.30M | 5.39% | — | 1.30M | — | — | CO | Israel | 2024-02-08 | ↗ |
| 32 | Sphera Global Healthcare GP Ltd. | 1.30M | 5.39% | — | 1.30M | — | — | CO | Israel | 2024-02-08 | ↗ |
| 33 | Sphera Global Healthcare Management LP | 1.30M | 5.39% | — | 1.30M | — | — | PN | Israel | 2024-02-08 | ↗ |
| 34 | Brian D. Ladin | 1.06M | 6.50% | — | 1.06M | — | — | IN | United States of America | 2015-04-20 | ↗ |
| 35 | TC Global Management LLC | 515.9K | 3.20% | — | 515.9K | — | — | OO | Delaware | 2015-04-20 | ↗ |
| 36 | Southern Investments I LLC | 299.6K | 1.80% | — | 299.6K | — | — | OO | Delaware | 2015-04-20 | ↗ |
| 37 | BRL Family LLC | 249.1K | 1.50% | — | 249.1K | — | — | OO | Texas | 2015-04-20 | ↗ |
| 38 | BRL TX-Family LP | 249.1K | 1.50% | — | 249.1K | — | — | PN | Texas | 2015-04-20 | ↗ |
| 39 | RS Holdings, Inc. | 18.8K | 0.10% | — | 18.8K | — | — | CO | Texas | 2015-04-20 | ↗ |
| 40 | YOSBANI MENDEZ | 2.4K | 0.00% | — | — | — | — | IN | : | 2014-11-12 | ↗ |
| 41 | Delos Investment Management LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2015-04-20 | ↗ |
| 42 | Lennox Capital Partners, LP | — | 0.00% | — | — | — | — | PN | Texas | 2015-04-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-41 vs prev Q
New positions
3
Closed positions
43
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | 5AM VENTURE MANAGEMENT, LLC | 9.68M +— (+0.0%) | 7.26M -30.8M (-80.9%) | 24.41% -0.004 pp | 2.28% -11.653 pp | USD8.06 -90.7% | 7 qtrs — |
| 2 | VERSANT VENTURE MANAGEMENT, LLC | 2.01M +— (+0.0%) | 1.51M -6.4M (-80.9%) | 5.06% -0.001 pp | 1.00% -2.718 pp | USD14.18 -94.7% | 8 qtrs — |
| 3 | BAKER BROS. ADVISORS LP | 1.45M +— (+0.0%) | 1.09M -4.6M (-80.9%) | 3.66% -0.001 pp | 0.01% -0.035 pp | USD5.33 -85.9% | 7 qtrs — |
| 4 | VANGUARD GROUP INC | 882.8K +— (+0.0%) | 662.1K -2.8M (-80.9%) | 2.23% 0.000 pp | 0.00% +0.000 pp | USD7.12 -89.5% | 7 qtrs — |
| 5 | SPHERA FUNDS MANAGEMENT LTD. | 478.9K +— (+0.0%) | 359.1K -1.5M (-80.9%) | 1.21% 0.000 pp | 0.07% -0.328 pp | USD7.35 -89.8% | 7 qtrs — |
| 6 | MILLENNIUM MANAGEMENT LLC | 380.5K -21.9K (-5.4%) | 285.2K -1.3M (-82.0%) | 0.96% -0.055 pp | 0.00% -0.001 pp | USD4.18 -82.1% | 3 qtrs — |
| 7 | BLACKROCK, INC. | 281.8K +2.0K (+0.7%) | 211.3K -888.6K (-80.8%) | 0.71% +0.005 pp | 0.00% +0.000 pp | USD3.86 -80.6% | 6 qtrs — |
| 8 | PLATINUM INVESTMENT MANAGEMENT LTD | 233.1K +— (+0.0%) | 174.8K -741.3K (-80.9%) | 0.59% 0.000 pp | 0.04% -0.019 pp | USD3.91 -80.8% | 6 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 210.2K +1.6K (+0.7%) | 157.6K -662.5K (-80.8%) | 0.53% +0.004 pp | 0.00% +0.000 pp | USD7.01 -89.3% | 7 qtrs — |
| 10 | SCHONFELD STRATEGIC ADVISORS LLC | 93.4K -1.1M (-92.1%) | 70.0K -4.6M (-98.5%) | 0.24% -2.758 pp | 0.00% -0.026 pp | USD4.39 -82.9% | 7 qtrs — |
| 11 | STATE STREET CORP | 75.3K +— (+0.0%) | 56.5K -239.6K (-80.9%) | 0.19% +0.000 pp | 0.00% +0.000 pp | USD7.11 -89.5% | 7 qtrs — |
| 12 | XTX TOPCO LTD | 53.0K +53.0K (+100.0%) | 39.8K +39.8K (+100.0%) | 0.13% +0.134 pp | 0.00% +0.001 pp | USD0.75 +0.0% | 1 qtrs NEW |
| 13 | TWO SIGMA INVESTMENTS, LP | 51.7K -40.6K (-44.0%) | 38.8K -324.0K (-89.3%) | 0.13% -0.102 pp | 0.00% -0.001 pp | USD3.64 -79.4% | 4 qtrs — |
| 14 | TWO SIGMA ADVISERS, LP | 41.0K +41.0K (+100.0%) | 30.7K +30.7K (+100.0%) | 0.10% +0.103 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 1 qtrs NEW |
| 15 | HRT FINANCIAL LP | 27.3K +27.3K (+100.0%) | 20.0K +20.0K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 3 qtrs — |
| 16 | JANE STREET GROUP, LLC | 24.6K +11.9K (+93.3%) | 18.5K -31.6K (-63.1%) | 0.06% +0.030 pp | 0.00% +0.000 pp | USD2.40 -68.8% | 2 qtrs — |
| 17 | ENGINEERS GATE MANAGER LP | 23.1K +23.1K (+100.0%) | 17.3K +17.3K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 1 qtrs NEW |
| 18 | GSA CAPITAL PARTNERS LLP | 22.9K +22.9K (+100.0%) | 17.0K +17.0K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.002 pp | USD0.75 +0.0% | 1 qtrs NEW |
| 19 | BARCLAYS PLC | 21.3K -36.6K (-63.3%) | 15.9K -210.4K (-93.0%) | 0.05% -0.092 pp | 0.00% 0.000 pp | USD3.93 -80.9% | 7 qtrs — |
| 20 | NORTHERN TRUST CORP | 20.1K -8.9K (-30.6%) | 15.1K -98.9K (-86.8%) | 0.05% -0.022 pp | 0.00% +0.000 pp | USD5.11 -85.3% | 7 qtrs — |
| 21 | CITADEL ADVISORS LLC | 18.0K +18.0K (+100.0%) | 13.5K +13.5K (+100.0%) | 0.05% +0.045 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 3 qtrs — |
| 22 | GROUP ONE TRADING, L.P. | 17.7K +15.3K (+634.3%) | 13.3K +3.8K (+40.1%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD1.18 -36.4% | 2 qtrs — |
| 23 | R SQUARED LTD | 14.8K +14.8K (+100.0%) | 11.1K +11.1K (+100.0%) | 0.04% +0.037 pp | 0.01% +0.005 pp | USD0.75 +0.0% | 1 qtrs NEW |
| 24 | UBS GROUP AG | 13.3K -16.7K (-55.7%) | 10.0K -107.9K (-91.5%) | 0.03% -0.042 pp | 0.00% +0.000 pp | USD2.41 -68.9% | 7 qtrs — |
| 25 | CAPITAL ADVISORS INC/OK | 10.0K +— (+0.0%) | 7.5K -31.8K (-80.9%) | 0.03% +0.000 pp | 0.00% -0.001 pp | USD3.93 -80.9% | 2 qtrs — |
| 26 | SIMPLEX TRADING, LLC | 6.3K +6.3K (+100.0%) | 4.7K +4.7K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 3 qtrs — |
| 27 | MORGAN STANLEY | 4.3K -683.0 (-13.8%) | 3.2K -16.3K (-83.6%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD5.31 -85.9% | 7 qtrs — |
| 28 | FEDERATED HERMES, INC. | 1.2K +1.2K (+100.0%) | 868.00 +868.0 (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 3 qtrs — |
| 29 | FMR LLC | 748.00 -11.1K (-93.7%) | 561.00 -46.1K (-98.8%) | 0.00% -0.028 pp | 0.00% +0.000 pp | USD3.76 -80.1% | 6 qtrs — |
| 30 | BANK OF AMERICA CORP /DE/ | 586.00 +445.0 (+315.6%) | 438.00 -116.0 (-20.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.73 -56.6% | 7 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 510.00 +— (+0.0%) | 382.00 -1.6K (-80.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.84 -87.2% | 7 qtrs — |
| 32 | NATIONAL BANK OF CANADA /FI/ | 400.00 +400.0 (+100.0%) | 295.00 +295.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.75 +0.0% | 1 qtrs NEW |
| 33 | FORTITUDE FAMILY OFFICE, LLC | 385.00 +271.0 (+237.7%) | 289.00 -159.0 (-35.5%) | 0.00% +0.001 pp | 0.00% 0.000 pp | USD1.69 -55.6% | 2 qtrs — |
| 34 | JPMORGAN CHASE & CO | 66.00 +66.0 (+100.0%) | 49.00 +49.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.74 +1.4% | 1 qtrs NEW |
| 35 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 52.00 -29.2K (-99.8%) | 39.00 -115.0K (-100.0%) | 0.00% -0.074 pp | 0.00% 0.000 pp | USD3.23 -76.8% | 5 qtrs — |
| 36 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 51.00 +— (+0.0%) | 38.00 -162.0 (-81.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.06 -90.7% | 7 qtrs — |
| 37 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 39.00 +— (+0.0%) | 29.00 -124.0 (-81.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.92 -80.9% | 2 qtrs — |
| 38 | TD WATERHOUSE CANADA INC. | 25.00 +— (+0.0%) | 18.00 -89.0 (-83.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.24 -76.9% | 7 qtrs — |
| 39 | OPTIVER HOLDING B.V. | 20.00 +— (+0.0%) | 15.00 -64.0 (-81.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.90 -80.8% | 2 qtrs — |
| 40 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 18.00 +— (+0.0%) | 13.00 -58.0 (-81.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.06 -90.7% | 7 qtrs — |
| 41 | DYNAMIC WEALTH STRATEGIES, LLC | 8.00 +8.0 (+100.0%) | 6.00 +6.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.63 +19.0% | 1 qtrs NEW |
| 42 | CORECAP ADVISORS, LLC | 8.00 +8.0 (+100.0%) | 6.00 +6.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.63 +19.0% | 1 qtrs NEW |
| 43 | — | 2.00 +2.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +50.0% | 1 qtrs NEW |
| 44 | PLANTE MORAN FINANCIAL ADVISORS, LLC | 3.00 +— (+0.0%) | 2.00 -10.0 (-83.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 -90.6% | 7 qtrs — |
| 45 | WELLS FARGO & COMPANY/MN | 1.00 +— (+0.0%) | 1.00 -3.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.00 -87.5% | 7 qtrs — |
| 46 | HARBOUR INVESTMENTS, INC. | 1.00 +— (+0.0%) | 1.00 -3.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 -90.6% | 7 qtrs — |
| 47 | ADVISOR GROUP HOLDINGS, INC. | 2.00 -16.0 (-88.9%) | 1.00 -62.0 (-98.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 -81.3% | 6 qtrs — |
| 48 | IFP ADVISORS, INC | 1.00 +— (+0.0%) | 1.00 -3.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -75.0% | 2 qtrs — |
| 49 | TUCKER ASSET MANAGEMENT LLC | 1.00 +1.0 (+100.0%) | 1.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 1 qtrs NEW |
| 50 | PFS PARTNERS, LLC | 1.00 +— (+0.0%) | 1.00 -3.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 -90.6% | 7 qtrs — |
| 51 | LPL FINANCIAL LLC | — -25.5K (-100.0%) | — -100.3K (-100.0%) | 0.00% -0.064 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 52 | ALYESKA INVESTMENT GROUP, L.P. | — -456.2K (-100.0%) | — -1.8M (-100.0%) | 0.00% -1.150 pp | 0.00% -0.005 pp | USD— | 7 qtrs SOLD |
| 53 | BOOTHBAY FUND MANAGEMENT, LLC | — -26.6K (-100.0%) | — -104.5K (-100.0%) | 0.00% -0.067 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 54 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | — -42.0K (-100.0%) | — -165.1K (-100.0%) | 0.00% -0.106 pp | 0.00% -0.004 pp | USD— | 6 qtrs SOLD |
| 55 | CAPITAL ADVISORS WEALTH MANAGEMENT, LLC | — -44.5K (-100.0%) | — -175.0K (-100.0%) | 0.00% -0.112 pp | 0.00% -0.025 pp | USD— | 4 qtrs SOLD |
| 56 | CITIGROUP INC | — -1.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 57 | DEUTSCHE BANK AG\ | — -5.9K (-100.0%) | — -23.3K (-100.0%) | 0.00% -0.015 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 58 | DIADEMA PARTNERS LP | — -300.0K (-100.0%) | — -1.2M (-100.0%) | 0.00% -0.756 pp | 0.00% -0.302 pp | USD— | 2 qtrs SOLD |
| 59 | DIMENSIONAL FUND ADVISORS LP | — -13.4K (-100.0%) | — -52.7K (-100.0%) | 0.00% -0.034 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 60 | DRIEHAUS CAPITAL MANAGEMENT LLC | — -620.4K (-100.0%) | — -2.4M (-100.0%) | 0.00% -1.564 pp | 0.00% -0.018 pp | USD— | 7 qtrs SOLD |
| 61 | ENSIGN PEAK ADVISORS, INC | — -767.3K (-100.0%) | — -3.0M (-100.0%) | 0.00% -1.935 pp | 0.00% -0.005 pp | USD— | 6 qtrs SOLD |
| 62 | GOLDMAN SACHS GROUP INC | — -73.1K (-100.0%) | — -287.4K (-100.0%) | 0.00% -0.184 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 63 | GROUPE LA FRANCAISE | — -14.0 (-100.0%) | — -46.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 64 | MAI CAPITAL MANAGEMENT | — -32.0 (-100.0%) | — -126.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 65 | MARSHALL WACE, LLP | — -251.6K (-100.0%) | — -989.0K (-100.0%) | 0.00% -0.635 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
| 66 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | — -269.7K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.680 pp | 0.00% -0.002 pp | USD— | 6 qtrs SOLD |
| 67 | QUADRATURE CAPITAL LTD | — -16.4K (-100.0%) | — -64.8K (-100.0%) | 0.00% -0.041 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 68 | QUBE RESEARCH & TECHNOLOGIES LTD | — -16.7K (-100.0%) | — -65.5K (-100.0%) | 0.00% -0.042 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 69 | ROYAL BANK OF CANADA | — -401.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 70 | SRS CAPITAL ADVISORS, INC. | — -9.0 (-100.0%) | — -35.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 71 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -28.8K (-100.0%) | — -113.2K (-100.0%) | 0.00% -0.073 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 72 | TOWER RESEARCH CAPITAL LLC (TRC) | — -4.4K (-100.0%) | — -17.4K (-100.0%) | 0.00% -0.011 pp | 0.00% -0.001 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 140.2K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 923.46 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.5K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 187.29 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 433.3K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 949.09 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 516.45 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 208.77 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 23.03 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 3.24 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.06
Bullish
Ratio by volume
1.72
Bullish
Buys
35
Sells
17
Shares acquired
3.32M
Shares disposed
1.93M
Cash buys
—
Cash sales
—
Net activity
+1,390,211
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Twitty Christopher | Officer | D-Return | D | Stock Option (Right to Buy) | 75,000 | 14.56 | 1.09M | 0 | D | ↗ |
| 2026-03-31 | Smith Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.62 | 46.1K | 75,000 | D | ↗ |
| 2026-03-31 | Sharp John P | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-31 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.62 | 46.1K | 75,000 | D | ↗ |
| 2026-03-31 | Jenkins Annalisa | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.62 | 46.1K | 75,000 | D | ↗ |
| 2026-03-31 | Grayson Paul A. | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.62 | 46.1K | 75,000 | D | ↗ |
| 2026-03-31 | Diep Tuan Tu | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.62 | 46.1K | 75,000 | D | ↗ |
| 2026-03-31 | DHILLON PUNIT | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.62 | 399.8K | 650,000 | D | ↗ |
| 2026-03-31 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.62 | 46.1K | 75,000 | D | ↗ |
| 2026-02-06 | Twitty Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.82 | 123.0K | 150,000 | D | ↗ |
| 2026-02-06 | Smith Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.82 | 28.7K | 35,000 | D | ↗ |
| 2026-02-06 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.82 | 28.7K | 35,000 | D | ↗ |
| 2026-02-06 | Jenkins Annalisa | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.82 | 28.7K | 35,000 | D | ↗ |
| 2026-02-06 | Grayson Paul A. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.82 | 28.7K | 35,000 | D | ↗ |
| 2026-02-06 | Diep Tuan Tu | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.82 | 102.5K | 125,000 | D | ↗ |
| 2026-02-06 | DHILLON PUNIT | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 0.82 | 229.6K | 280,000 | D | ↗ |
| 2026-02-06 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.82 | 28.7K | 35,000 | D | ↗ |
| 2026-02-06 | Arora Puneet S. | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.82 | 102.5K | 125,000 | D | ↗ |
| 2026-02-06 | ARSENAULT KAITLYN | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.82 | 102.5K | 125,000 | D | ↗ |
| 2025-08-22 | Schwab Andrew J. | Director / 10% Owner | S-Sale | D | Common Stock | 163,979 | 3.42 | 560.8K | 1,457,064 | I | ↗ |
| 2025-08-22 | 5AM Partners VII, LLC | 10% Owner | S-Sale | D | Common Stock | 6,470 | 3.42 | 22.1K | 57,493 | I | ↗ |
| 2025-08-21 | Schwab Andrew J. | Director / 10% Owner | S-Sale | D | Common Stock | 2,314 | 3.57 | 8.3K | 63,963 | I | ↗ |
| 2025-08-21 | 5AM Partners VII, LLC | 10% Owner | S-Sale | D | Common Stock | 2,314 | 3.57 | 8.3K | 63,963 | I | ↗ |
| 2025-04-23 | Twitty Christopher | Officer | — | — | Common Stock | 0 | 0.00 | — | 81,242 | D | ↗ |
| 2025-02-24 | Smith Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.89 | 101.2K | 35,000 | D | ↗ |
| 2025-02-24 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.89 | 101.2K | 35,000 | D | ↗ |
| 2025-02-24 | Jenkins Annalisa | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.89 | 101.2K | 35,000 | D | ↗ |
| 2025-02-24 | Grayson Paul A. | Director | A-Award | A | Stock Option (Right to Buy) | 135,000 | 2.89 | 390.2K | 135,000 | D | ↗ |
| 2025-02-24 | Diep Tuan Tu | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.89 | 433.5K | 150,000 | D | ↗ |
| 2025-02-24 | DHILLON PUNIT | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 2.89 | 722.5K | 250,000 | D | ↗ |
| 2025-02-24 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.89 | 101.2K | 35,000 | D | ↗ |
| 2025-02-24 | Arora Puneet S. | Officer | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.89 | 109.8K | 38,000 | D | ↗ |
| 2025-02-24 | ARSENAULT KAITLYN | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 2.89 | 433.5K | 150,000 | D | ↗ |
| 2024-11-18 | Grayson Paul A. | Director | S-Sale | D | Common Stock | 86,244 | 4.99 | 430.4K | 259,701 | D | ↗ |
| 2024-11-18 | Diep Tuan Tu | Officer | S-Sale | D | Common Stock | 19,489 | 4.99 | 97.3K | 82,259 | D | ↗ |
| 2024-11-18 | DHILLON PUNIT | Director / Officer | S-Sale | D | Common Stock | 82,546 | 4.99 | 411.9K | 329,823 | D | ↗ |
| 2024-11-18 | ARSENAULT KAITLYN | Officer | S-Sale | D | Common Stock | 43,026 | 4.99 | 214.7K | 167,522 | D | ↗ |
| 2024-11-15 | Grayson Paul A. | Director | S-Sale | D | Common Stock | 307 | 5.55 | 1.7K | 345,945 | D | ↗ |
| 2024-11-15 | Diep Tuan Tu | Officer | S-Sale | D | Common Stock | 85 | 5.55 | 471.75 | 101,748 | D | ↗ |
| 2024-11-15 | DHILLON PUNIT | Director / Officer | S-Sale | D | Common Stock | 364 | 5.55 | 2.0K | 412,369 | D | ↗ |
| 2024-11-15 | ARSENAULT KAITLYN | Officer | S-Sale | D | Common Stock | 190 | 5.55 | 1.1K | 210,548 | D | ↗ |
| 2024-10-28 | Smith Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.15 | 360.5K | 70,000 | D | ↗ |
| 2024-10-28 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.15 | 360.5K | 70,000 | D | ↗ |
| 2024-10-28 | Jenkins Annalisa | Director | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.15 | 360.5K | 70,000 | D | ↗ |
| 2024-10-28 | Grayson Paul A. | Director | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.15 | 360.5K | 70,000 | D | ↗ |
| 2024-10-28 | Diep Tuan Tu | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 5.15 | 643.8K | 125,000 | D | ↗ |
| 2024-10-28 | DHILLON PUNIT | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 5.15 | 3.35M | 650,000 | D | ↗ |
| 2024-10-28 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.15 | 360.5K | 70,000 | D | ↗ |
| 2024-10-28 | ARSENAULT KAITLYN | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 5.15 | 643.8K | 125,000 | D | ↗ |
| 2024-09-13 | Schwab Andrew J. | Director / 10% Owner | S-Sale | D | Common Stock | 11,758 | 6.06 | 71.3K | 8,167,206 | — | ↗ |
| 2024-09-13 | 5AM Partners VII, LLC | 10% Owner | S-Sale | D | Common Stock | 2,000 | 6.06 | 12.1K | 1,679,685 | — | ↗ |
| 2024-09-11 | Schwab Andrew J. | Director / 10% Owner | S-Sale | D | Common Stock | 214,556 | 6.60 | 1.42M | 8,178,964 | — | ↗ |
| 2024-09-11 | 5AM Partners VII, LLC | 10% Owner | S-Sale | D | Common Stock | 214,556 | 6.60 | 1.42M | 8,178,964 | — | ↗ |
| 2024-09-03 | Arora Puneet S. | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 5.89 | 1.33M | 225,000 | — | ↗ |
| 2024-08-26 | DHILLON PUNIT | Director / Officer | J-Other | A | Common Stock | 15,727 | 0.00 | — | 412,733 | — | ↗ |
| 2024-07-02 | Smith Karen L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-13 | Schwab Andrew J. | Director / 10% Owner | A-Award | A | Common Stock | 450,000 | 10.00 | 4.50M | 8,393,520 | — | ↗ |
| 2024-03-13 | 5AM Partners VII, LLC | 10% Owner | P-Purchase | A | Common Stock | 450,000 | 10.00 | 4.50M | 8,393,520 | — | ↗ |
| 2024-03-04 | Diep Tuan Tu | Officer | — | — | Common Stock | 0 | 0.00 | — | 72,833 | D | ↗ |
| 2024-02-29 | Ward Keith Wayne | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 14.56 | 509.6K | 35,000 | — | ↗ |
| 2024-02-29 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 14.56 | 509.6K | 35,000 | — | ↗ |
| 2024-02-29 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 14.56 | 509.6K | 35,000 | — | ↗ |
| 2024-02-29 | Jenkins Annalisa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-29 | Grayson Paul A. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 14.56 | 509.6K | 35,000 | — | ↗ |
| 2024-02-29 | Diep Tuan Tu | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-29 | DHILLON PUNIT | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 397,006 | — | ↗ |
| 2024-02-29 | DALESANDRO MARGARET | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 14.56 | 509.6K | 35,000 | — | ↗ |
| 2024-02-29 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 14.56 | 509.6K | 35,000 | — | ↗ |
| 2024-02-29 | ARSENAULT KAITLYN | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 14.56 | 1.09M | 75,000 | — | ↗ |
| 2024-01-31 | Schwab Andrew J. | Director / 10% Owner | A-Award | A | Common Stock | 5,206,074 | 2.31 | 12.03M | 7,943,520 | — | ↗ |
| 2024-01-31 | 5AM Partners VII, LLC | 10% Owner | P-Purchase | A | Common Stock | 5,206,074 | 2.31 | 12.03M | 7,943,520 | — | ↗ |
| 2023-11-06 | Ward Keith Wayne | Director | A-Award | A | Stock Option (Right to Buy) | 14,110 | 3.50 | 49.4K | 20,001 | — | ↗ |
| 2023-11-06 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (Right to Buy) | 14,110 | 3.50 | 49.4K | 20,001 | — | ↗ |
| 2023-11-06 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 14,110 | 3.50 | 49.4K | 20,001 | — | ↗ |
| 2023-11-06 | Grayson Paul A. | Director | A-Award | A | Common Stock | 173,721 | 0.00 | — | 246,252 | — | ↗ |
| 2023-11-06 | DHILLON PUNIT | Director / Officer | A-Award | A | Common Stock | 194,270 | 0.00 | — | 297,006 | — | ↗ |
| 2023-11-06 | DALESANDRO MARGARET | Director | A-Award | A | Stock Option (Right to Buy) | 14,110 | 3.50 | 49.4K | 20,001 | — | ↗ |
| 2023-11-06 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 14,110 | 3.50 | 49.4K | 20,001 | — | ↗ |
| 2023-11-06 | ARSENAULT KAITLYN | Officer | A-Award | A | Common Stock | 128,209 | 0.00 | — | 185,738 | — | ↗ |
| 2023-08-29 | DHILLON PUNIT | Director / Officer | P-Purchase | A | Common Stock | 881,000 | 0.02 | 16.5K | 25,683,957 | — | ↗ |
| 2023-08-28 | DHILLON PUNIT | Director / Officer | L-Small | A | Common Stock | 110,000 | 0.02 | 1.9K | 24,802,957 | — | ↗ |
| 2023-08-25 | Ward Keith Wayne | Director | A-Award | A | Stock Option (Right to Buy) | 1,472,692 | 0.01 | 20.6K | 1,472,692 | — | ↗ |
| 2023-08-25 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (Right to Buy) | 1,472,692 | 0.01 | 20.6K | 1,472,692 | — | ↗ |
| 2023-08-25 | Schwab Andrew J. | Director | A-Award | A | Stock Option (Right to Buy) | 1,472,692 | 0.01 | 20.6K | 1,472,692 | — | ↗ |
| 2023-08-25 | Grayson Paul A. | Director | A-Award | A | Common Stock | 18,132,596 | 0.00 | — | 18,132,596 | — | ↗ |
| 2023-08-25 | DHILLON PUNIT | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,253,046 | 0.01 | 31.5K | 2,253,046 | — | ↗ |
| 2023-08-25 | DALESANDRO MARGARET | Director | A-Award | A | Stock Option (Right to Buy) | 1,472,692 | 0.01 | 20.6K | 1,472,692 | — | ↗ |
| 2023-08-25 | Charych Deborah H. | Director | A-Award | A | Stock Option (Right to Buy) | 1,472,692 | 0.01 | 20.6K | 1,472,692 | — | ↗ |
| 2023-08-25 | ARSENAULT KAITLYN | Officer | A-Award | A | Common Stock | 13,382,118 | 0.00 | — | 14,382,118 | — | ↗ |
| 2023-08-23 | DHILLON PUNIT | Director / Officer | L-Small | A | Common Stock | 9,000 | 0.01 | 106.20 | 24,692,957 | — | ↗ |
| 2023-08-18 | Versant Ventures III, LLC | 10% Owner | — | I | Warrant (Right to Buy) | 768,124 | 0.02 | 15.8K | 0 | — | ↗ |
| 2023-08-18 | Schwab Andrew J. | Director / 10% Owner | A-Award | A | Common Stock | 684,361,447 | 0.01 | 7.05M | 684,361,447 | — | ↗ |
| 2023-08-18 | Grayson Paul A. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-18 | 5AM Partners VII, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 684,361,447 | — | ↗ |
| 2023-03-01 | Charych Deborah H. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-22 | Emerald Health Sciences Inc. | 10% Owner | D-Return | D | Warrants with Credit Facility of Oct 5, 2018 - T3 | 2,500,000 | 0.04 | 96.5K | 0 | — | ↗ |
| 2023-02-14 | Charych Deborah H. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-05 | Ward Keith Wayne | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2023-01-05 | TYLE PRAVEEN | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2023-01-05 | Rai Sukhwinder Singh | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.02 | 4.3K | 250,000 | — | ↗ |
| 2023-01-05 | DALESANDRO MARGARET | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-11-15 | Rai Sukhwinder Singh | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-11-10 | Rai Sukhwinder Singh | Director | A-Award | A | Stock Option (Right to Buy) | 390,000 | 0.00 | — | 390,000 | — | ↗ |
| 2022-11-10 | Emerald Health Sciences Inc. | 10% Owner | J-Other | A | Warrants | 9,141,486 | 0.15 | 1.38M | 9,141,486 | — | ↗ |
| 2022-11-10 | DHILLON PUNIT | Officer | A-Award | A | Common Stock | 2,335,721 | 0.00 | — | 2,335,721 | — | ↗ |
| 2021-12-14 | Ward Keith Wayne | Director | A-Award | A | Director Option Grant (Right to Buy) | 250,000 | 0.06 | 14.5K | 250,000 | — | ↗ |
| 2021-12-14 | DHILLON PUNIT | Director / Officer | A-Award | A | Common Stock | 2,000,000 | 0.00 | — | 3,000,000 | — | ↗ |
| 2021-12-14 | Arsenault Kaitlyn Melanie | Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2021-10-04 | Arsenault Kaitlyn Melanie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,600,000 | 0.09 | 144.0K | 2,000,000 | — | ↗ |
| 2021-09-14 | TYLE PRAVEEN | Director | A-Award | A | Director Stock Option (Right to Buy) | 25,000 | 0.12 | 3.0K | 275,000 | — | ↗ |
| 2021-09-14 | HEPPELL JAMES L | Director | A-Award | A | Director Stock Option (Right to Buy) | 150,000 | 0.12 | 18.0K | 1,350,000 | — | ↗ |
| 2021-09-14 | DALESANDRO MARGARET | Director | A-Award | A | Director Stock Option (Right to Buy) | 150,000 | 0.12 | 18.0K | 400,000 | — | ↗ |
| 2021-07-22 | TYLE PRAVEEN | Director | A-Award | A | Director Option Grant (Right to Buy) | 250,000 | 0.14 | 35.0K | 250,000 | — | ↗ |
| 2020-09-25 | Janney Richard | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-07 | Traistaru Elena | Officer | A-Award | A | Consultant Option Grant (Right to Buy) | 1,000,000 | 0.05 | 45.0K | 1,000,000 | — | ↗ |
| 2020-08-07 | KIM DENNIS D | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 4,000,000 | 0.05 | 180.0K | 4,736,541 | — | ↗ |
| 2020-08-07 | HEPPELL JAMES L | Director | A-Award | A | Director Option Grant (Right to Buy) | 1,000,000 | 0.05 | 45.0K | 1,200,000 | — | ↗ |
| 2020-08-07 | Emerald Health Sciences Inc. | 10% Owner | S-Sale | D | Common Stock | 2,566,666 | 0.10 | 256.7K | 123,923,501 | — | ↗ |
| 2020-08-07 | DHILLON PUNIT | Director / Officer | A-Award | A | Employee Option Grant (Right to Buy) | 9,000,000 | 0.05 | 405.0K | 9,200,000 | — | ↗ |
| 2020-08-07 | DALESANDRO MARGARET | Director | A-Award | A | Director Option Grant (Right to Buy) | 250,000 | 0.05 | 11.3K | 250,000 | — | ↗ |
| 2020-05-15 | Traistaru Elena | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-20 | Emerald Health Sciences Inc. | 10% Owner | J-Other | D | 7% Convertible Debt | 4,080,000 | 0.40 | 1.63M | 5,036,250 | — | ↗ |
| 2019-08-21 | KIM DENNIS D | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-29 | Emerald Health Sciences Inc. | 10% Owner | A-Award | A | Warrants with Credit Facility of Oct 5, 2018 | 2,500,000 | 0.50 | 1.25M | 2,500,000 | — | ↗ |
| 2019-02-01 | Emerald Health Sciences Inc. | 10% Owner | A-Award | A | Multi Draw Credit Facility - T2 | 38,822 | 0.40 | 15.5K | 38,822 | — | ↗ |
| 2018-12-27 | Emerald Health Sciences Inc. | 10% Owner | J-Other | A | Common Stock | 37,667 | 0.10 | 3.8K | 73,153,917 | — | ↗ |
| 2018-11-01 | Emerald Health Sciences Inc. | 10% Owner | J-Other | A | 7% Convertible Debt | 0 | 0.40 | — | 0 | — | ↗ |
| 2018-10-10 | HEPPELL JAMES L | Director | A-Award | A | Director Stock Option (Right to Buy) | 200,000 | 0.31 | 61.0K | 200,000 | — | ↗ |
| 2018-10-10 | DHILLON PUNIT | Director | A-Award | A | Director Stock Option (Right to Buy) | 200,000 | 0.31 | 61.0K | 200,000 | — | ↗ |
| 2018-10-10 | DHILLON AVTAR S | Director | A-Award | A | Director Stock Option (Right to Buy) | 1,000,000 | 0.31 | 305.0K | 1,000,000 | — | ↗ |
| 2018-10-05 | DHILLON AVTAR S | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-07-23 | Cesario Douglas A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,195,073 | 0.25 | 292.8K | 1,195,073 | — | ↗ |
| 2018-05-25 | Cesario Douglas A | Officer | — | D | No securities beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-29 | Emerald Health Sciences Inc. | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 1,234 | 0.10 | 123.35 | 0 | — | ↗ |
| 2018-02-16 | Emerald Health Sciences Inc. | 10% Owner | P-Purchase | A | Common Stock | 15,000,000 | 0.00 | 15.0K | 39,000,000 | — | ↗ |
| 2018-01-24 | Emerald Health Sciences Inc. | 10% Owner | X-InTheMoney | A | Common Stock | 1,781,250 | 0.00 | 1.8K | 40,781,250 | — | ↗ |
| 2018-01-18 | Murphy Brian Stuart | Director / Officer | A-Award | A | Common Stock | 900,000 | 0.00 | — | 1,275,000 | — | ↗ |
| 2018-01-18 | LYKOS COSMAS N | Director / Officer / 10% Owner | A-Award | A | Common Stock | 900,000 | 0.00 | — | 4,599,400 | — | ↗ |
| 2018-01-18 | HEPPELL JAMES L | Director | — | D | No securities beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-18 | Emerald Health Sciences Inc. | 10% Owner | — | D | Common Stock Warrants (right to buy) | 20,400,000 | 0.10 | 2.04M | 0 | — | ↗ |
| 2018-01-18 | DHILLON PUNIT | Director | — | D | No securities beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-18 | Berecz Elizabeth | Officer | A-Award | A | Common Stock | 700,000 | 0.00 | — | 1,050,000 | — | ↗ |
| 2017-03-13 | Lapham Reg Alexander | 10% Owner | X-InTheMoney | D | Common Stock | 119,700 | 1.00 | 119.7K | 3,787,500 | — | ↗ |
| 2015-10-20 | Murphy Brian Stuart | Director / Officer | A-Award | A | Common Stock | 375,000 | 0.00 | — | 375,000 | — | ↗ |
| 2015-10-20 | McLaughlin Gerald W. | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 61,250 | — | ↗ |
| 2015-10-20 | LYKOS COSMAS N | Director / Officer / 10% Owner | A-Award | A | Common Stock | 325,000 | 0.00 | — | 3,699,400 | — | ↗ |
| 2015-10-20 | INGRAM DOUGLAS S | Director / Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 372,500 | — | ↗ |
| 2015-10-20 | GEORGE THOMAS | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2015-10-20 | Berecz Elizabeth | Officer | A-Award | A | Common Stock | 350,000 | 0.00 | — | 350,000 | — | ↗ |
| 2015-08-20 | McLaughlin Gerald W. | Director | C-Conversion | A | Common Stock | 31,250 | 0.00 | — | 31,250 | — | ↗ |
| 2015-08-20 | INGRAM DOUGLAS S | Director / Officer | C-Conversion | A | Common Stock | 312,500 | 0.00 | — | 312,500 | — | ↗ |
| 2015-06-04 | Squires Richard D. | 10% Owner | — | D | Common Stock Warrant (right to buy) | 371,250 | 1.00 | 371.3K | 0 | — | ↗ |
| 2015-06-01 | INGRAM DOUGLAS S | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.00 | 120.0K | 40,000 | — | ↗ |
| 2015-05-29 | McLaughlin Gerald W. | Director | P-Purchase | A | Common Stock Warrant (Right to Buy) | 2,000 | 5.00 | 10.0K | 2,000 | — | ↗ |
| 2015-04-10 | Ladin Brian D | 10% Owner | S-Sale | D | Common Stock | 11,830 | 4.93 | 58.3K | 249,098 | — | ↗ |
| 2015-04-08 | Ladin Brian D | 10% Owner | S-Sale | D | Common Stock | 23,000 | 4.69 | 107.9K | 276,728 | — | ↗ |
| 2015-04-07 | INGRAM DOUGLAS S | Director / Officer | — | D | Common Stock Warrant (Right to Buy) | 20,000 | 5.00 | 100.0K | 0 | — | ↗ |
| 2015-04-03 | Squires Richard D. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,485,000 | — | ↗ |
| 2015-01-09 | GEORGE THOMAS | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.00 | 120.0K | 40,000 | — | ↗ |
| 2014-12-10 | Ladin Brian D | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 329,228 | — | ↗ |
| 2014-12-04 | Murphy Brian Stuart | Officer | A-Award | A | Stock Option (Right to Buy) | 480,000 | 0.42 | 201.6K | 480,000 | — | ↗ |
| 2014-12-04 | McLaughlin Gerald W. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.42 | 8.4K | 20,000 | — | ↗ |
| 2014-12-04 | LYKOS COSMAS N | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.42 | 52.5K | 125,000 | — | ↗ |
| 2014-12-04 | Hollister John B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 480,000 | 0.42 | 201.6K | 480,000 | — | ↗ |
| 2014-12-04 | Berecz Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.42 | 63.0K | 150,000 | — | ↗ |
| 2014-10-31 | Murphy Brian Stuart | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-10-31 | Mendez Yosbani | — | J-Other | D | Common Stock | 4,251,460 | 0.00 | — | 2,440 | — | ↗ |
| 2014-10-31 | McLaughlin Gerald W. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-10-31 | MENDEZ FRANCISCO JAVIER | — | J-Other | D | Common Stock | 1,180,000 | 0.00 | — | 0 | — | ↗ |
| 2014-10-31 | Lapham Reg Alexander | 10% Owner | — | D | Warrant to Purchase Common Stock | 1,110,000 | 1.00 | 1.11M | 0 | — | ↗ |
| 2014-10-31 | LYKOS COSMAS N | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,374,400 | — | ↗ |
| 2014-10-31 | Hollister John B | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-10-31 | Berecz Elizabeth | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-01-28 | Mendez Yosbani | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,802,500 | — | ↗ |
| 2014-01-28 | MENDEZ FRANCISCO JAVIER | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
35.13M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Punit Dhillon Chief Executive Officer | 610.0K | — | — | 532.2K | 219.6K | — | 1.36M | 39.08% | ↗ |
| 2 | 2025 | Kaitlyn Arsenault Former Chief Financial Officer | 450.0K | — | — | 319.3K | 119.3K | — | 888.6K | 35.94% | ↗ |
| 3 | 2025 | Tu Diep Chief Operating Officer | 440.0K | — | — | 319.3K | 116.6K | — | 875.9K | 36.46% | ↗ |
| 4 | 2024 | Punit Dhillon Chief Executive Officer | 458.3K | — | 1.50M | 3.92M | 255.8K | — | 6.14M | 88.37% | ↗ |
| 5 | 2024 | Kaitlyn Arsenault Former Chief Financial Officer | 365.0K | — | 408.4K | 1.36M | 138.4K | — | 2.27M | 77.79% | ↗ |
| 6 | 2024 | Kaitlyn Arsenault Chief Financial Officer | 365.0K | — | 408.4K | 1.36M | 138.4K | — | 2.27M | 77.79% | ↗ |
| 7 | 2024 | Tu Diep Chief Operating Officer | 358.3K | — | 376.6K | 1.36M | 117.2K | — | 2.21M | 78.46% | ↗ |
| 8 | 2023 | Punit Dhillon Chief Executive Officer | 450.0K | — | 994.4K | 93.0K | 270.0K | — | 1.81M | 60.16% | ↗ |
| 9 | 2023 | Punit Dhillon CEO | 450.0K | — | 994.4K | 93.0K | 270.0K | — | 1.81M | 60.16% | ↗ |
| 10 | 2023 | Kaitlyn Arsenault Chief Financial Officer | 340.0K | — | 656.2K | 138.1K | 136.0K | — | 1.27M | 62.53% | ↗ |
| 11 | 2022 | Punit Dhillon CEO | 432.6K | 74.0K | — | — | 161.9K | — | 668.5K | 0.00% | ↗ |
| 12 | 2022 | Kaitlyn Arsenault Chief Financial Officer | 325.9K | 55.5K | — | — | 87.7K | — | 469.1K | 0.00% | ↗ |
| 13 | 2019 | Dr. Brian S. Murphy, CEO/CMO | 390.0K | — | — | — | — | — | 390.0K | 0.00% | ↗ |
| 14 | 2019 | Dr. Dennis Kim, CMO | 119.8K | — | — | 165.0K | — | — | 284.8K | 57.93% | ↗ |
| 15 | 2019 | Douglas Cesario, Former CFO | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 16 | 2019 | Avtar Dhillon, Former Executive Chairman | — | — | — | — | — | 117.9K | 117.9K | 0.00% | ↗ |
| 17 | 2018 | Dr. Brian S. Murphy, CEO/CMO | 390.0K | — | 171.0K | — | — | — | 561.0K | 30.48% | ↗ |
| 18 | 2018 | Douglas Cesario, Former CFO | 174.0K | — | 169.9K | 200.8K | — | — | 544.7K | 68.05% | ↗ |
| 19 | 2018 | Elizabeth M. Berecz, Former CFO | 246.8K | — | 133.0K | — | — | 19.3K | 399.1K | 33.33% | ↗ |
| 20 | 2018 | Cosmas N. Lykos, Former Chairman | — | — | 171.0K | — | — | 220.0K | 391.0K | 43.73% | ↗ |
| 21 | 2018 | Avtar Dhillon, Former Executive Chairman | — | — | — | 225.0K | — | 67.9K | 292.9K | 76.82% | ↗ |
| 22 | 2015 | Dr. Brian S. Murphy, CEO/CMO | 330.0K | — | 281.3K | — | — | — | 611.3K | 46.01% | ↗ |
| 23 | 2015 | Elizabeth M. Berecz, CFO | 225.0K | — | 262.5K | — | — | — | 487.5K | 53.85% | ↗ |
| 24 | 2015 | Cosmas N. Lykos, Chairman | — | — | 243.8K | — | — | 120.0K | 363.8K | 67.01% | ↗ |
| 25 | 2015 | John B. Hollister, former CEO | 268.1K | — | — | — | — | — | 268.1K | 0.00% | ↗ |
| 26 | 2014 | John B. Hollister CEO | 76.2K | — | — | 685.2K | — | — | 761.4K | 90.00% | ↗ |
| 27 | 2014 | John B. Hollister, former CEO | 76.2K | — | — | 656.4K | — | — | 732.6K | 89.60% | ↗ |
| 28 | 2014 | Dr. Brian S. Murphy, CMO | 63.5K | — | — | 617.0K | — | — | 680.4K | 90.67% | ↗ |
| 29 | 2014 | Dr. Brian S. Murphy, CEO/CMO | 63.5K | — | — | 588.2K | — | — | 651.6K | 90.26% | ↗ |
| 30 | 2014 | Elizabeth M. Berecz, CFO | 51.9K | — | — | 432.5K | — | — | 484.4K | 89.28% | ↗ |
| 31 | 2014 | Cosmas N. Lykos, Chairman | — | — | — | 341.3K | — | 20.0K | 361.3K | 94.46% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Punit S. Dhillon | President, CEO & Director | 829.6K | male |
| Tu Diep | Chief Operating Officer | 556.6K | male |
| Christopher G. Twitty | Chief Scientific Officer | — | — |
| John Sharp | CFO and Principal Financial & Accounting Officer | — | male |
| Puneet S. Arora FACE | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SKYE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
